日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

FDA批准摘要:Pirtobrutinib用于治疗复发或难治性套细胞淋巴瘤

Telaraja, Deepti; Kasamon, Yvette L; Collazo, Justin S; Leong, Ruby; Wang, Kun; Li, Ping; Dahmane, Elyes; Yang, Yuching; Earp, Justin; Grimstein, Manuela; Rodriguez, Lisa R; Theoret, Marc R; Gormley, Nicole J

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas

FDA批准摘要:Polatuzumab Vedotin用于特定大B细胞淋巴瘤的一线治疗

Sarraf Yazdy, Maryam; Kasamon, Yvette L; Gu, Wenjuan; Rodriguez, Lisa R; Jin, Susan; Bhatnagar, Vishal; Richardson, Nicholas C; Theoret, Marc R; Pazdur, Richard; Gormley, Nicole J

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

不可调和的差异:应答率、无进展生存期和总生存期之间的矛盾

Merino, Margret; Kasamon, Yvette; Theoret, Marc; Pazdur, Richard; Kluetz, Paul; Gormley, Nicole

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective

血液系统恶性肿瘤药物申请和标签中的微小残留病数据:FDA 的视角

Baines, Andrea C; Yazdy, Maryam Sarraf; Kasamon, Yvette L; Ershler, Rachel; Jen, Emily Y; Kanapuru, Bindu; Richardson, Nicholas C; Lane, Ashley; Carioti, Theresa; Theoret, Marc R; Pazdur, Richard; Gormley, Nicole J

FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

FDA批准摘要:Axicabtagene Ciloleucel用于大B细胞淋巴瘤二线治疗

Sharma, Poornima; Kasamon, Yvette L; Lin, Xue; Xu, Zhenzhen; Theoret, Marc R; Purohit-Sheth, Tejashri

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

HLA可用于预测单倍体相合造血干细胞移植后接受移植后环磷酰胺治疗的风险。

Fuchs, Ephraim J; McCurdy, Shannon R; Solomon, Scott R; Wang, Tao; Herr, Megan M; Modi, Dipenkumar; Grunwald, Michael R; Nishihori, Taiga; Kuxhausen, Michelle; Fingerson, Stephanie; McKallor, Caroline; Bashey, Asad; Kasamon, Yvette L; Bolon, Yung-Tsi; Saad, Ayman; McGuirk, Joseph; Paczesny, Sophie; Gadalla, Shahinaz M; Marsh, Steven G E; Shaw, Bronwen E; Spellman, Stephen R; Lee, Stephanie J; Petersdorf, Effie W

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

FDA批准摘要:Axicabtagene Ciloleucel用于治疗复发或难治性滤泡性淋巴瘤

Bouchkouj, Najat; Zimmerman, Megan; Kasamon, Yvette L; Wang, Cong; Dai, Tianjiao; Xu, Zhenzhen; Wang, Xiaofei; Theoret, Marc; Purohit-Sheth, Tejashri; George, Bindu

FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

FDA批准摘要:塞利尼索用于治疗复发或难治性弥漫性大B细胞淋巴瘤

Kasamon, Yvette L; Price, Lauren S L; Okusanya, Olanrewaju O; Richardson, Nicholas C; Li, Ruo-Jing; Ma, Lian; Wu, Yu-Te; Theoret, Marc; Pazdur, Richard; Gormley, Nicole J

Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study

异基因骨髓移植联合移植后环磷酰胺治疗HIV合并血液系统恶性肿瘤患者:一项可行性研究

Durand, Christine M; Capoferri, Adam A; Redd, Andrew D; Zahurak, Marianna; Rosenbloom, Daniel I S; Cash, Ayla; Avery, Robin K; Bolaños-Meade, Javier; Bollard, Catherine M; Bullen, C Korin; Flexner, Charles; Fuchs, Ephraim J; Gallant, Joel; Gladstone, Doug E; Gocke, Christopher D; Jones, Richard J; Kasamon, Yvette L; Lai, Jun; Levis, Mark; Luznik, Leo; Marr, Kieren A; McHugh, Holly L; Mehta Steinke, Seema; Pham, Paul; Pohlmeyer, Christopher; Pratz, Keith; Shoham, Shmuel; Wagner-Johnston, Nina; Xu, Daniel; Siliciano, Janet D; Quinn, Thomas C; Siliciano, Robert F; Ambinder, Richard F

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

ABVD联合利妥昔单抗对比ABVD单药治疗晚期高危经典型霍奇金淋巴瘤:一项随机II期研究

Strati, Paolo; Fanale, Michelle A; Oki, Yasuhiro; Turturro, Francesco; Fayad, Luis E; Bartlett, Nancy L; Gladstone, Douglas E; Kasamon, Yvette L; Portlock, Carol S; Wilson, Wyndham H; Goy, Andre; Younes, Anas; Lee, Hun Ju